This comparison suggests that inflammatory and neurodegenerative pathology in PPMS decrease with age, as the temporal dynamics of sNfL and sGFAP show an elevation of each biomarker in PPMS compared to SPG4, which is most pronounced in younger patients and lessens with age. This evidence concerns the gene SPAST and primary progressive multiple sclerosis.